Trimetazidine

Business Editors & Health/Medical Writers

NORTH HAMPTON, N.H.--(BUSINESS WIRE)--July 25, 2002

Will Release 2nd Quarter Financial Results August 6th

With Conference Call Scheduled for August 7th

Also Receives Two Product Approvals in Spain

Bentley Pharmaceuticals, Inc. (AMEX: BNT), a specialty pharmaceutical company focused on advanced drug-delivery technologies, which also manufactures and markets generic and branded products in Europe, announced today that it expects to report second quarter profitability on more than $10 million in sales, which represents 65% growth in revenues. The Company will release financial results on August 6th and hold a conference call on August 7th at 8:30 A.M.

Those who wish to participate in the conference call may telephone (888) 335-6674 fifteen minutes before the 8:30 A.M. starting time. A replay will be available by telephone for 30 days following the completion of the live call, at (877) 519-4471 toll free in the U.S. or (973) 341-3080 for international callers, PIN # 3407491.

The Company also announced that its subsidiaries have been granted approvals for branded products, in addition to the previously announced generic equivalents, for simvastatin and trimetazadine by the Spanish Ministry of Health. Laboratorios Davur is currently marketing a generic version of each product and Laboratorios Belmac will market branded versions under the tradenames of Simvascol(R) for simvastatin and Vaso Rimal(R) for trimetazadine. Simvastatin belongs to a class of lipid-lowering compounds used for controlling cholesterol and is marketed under the tradename Zocor(R), by Merck & Co. (NYSE: MRK). Trimetazidine belongs to a class of orally administered cardiovascular drugs used to control chest pain associated with angina.

James R. Murphy, Chairman and CEO, said, "We are looking forward to reporting the results of the second quarter that reflect continuing rapid top-line growth of 65 percent and continuing profitability in consecutive quarters. Furthermore, we have been anticipating and are very excited by the branded approval of the Simvascol and Vaso Rimal products. According to the IMS, the annual market for simvastatin in Spain is approximately $77 million and growing at a rate of 22% annually. These products, as well as other recent and pending approvals are expected to contribute to short-term growth of our Spanish subsidiaries Laboratorios Belmac and Laboratorios Davur."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Spain for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries Laboratorios Belmac and Laboratorios Davur.

Copies of the company's press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with identifying suitable drugs for drug delivery technologies, expanding generic and branded drug operations, development and commercialization of our products, relationships with our strategic partners, uncertainty of clinical trials, regulatory approval process, product sales concentration, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in Bentley's filings with the Securities and Exchange Commission

COPYRIGHT 2002 Business Wire
COPYRIGHT 2002 Gale Group